Targeting the adaptive molecular landscape of castration-resistant prostate cancer - Wikidata - wikimedia - TriplyDB

Targeting the adaptive molecular landscape of castration-resistant prostate cancer

Targeting the adaptive molecular landscape of castration-resistant prostate cancer

http://www.wikidata.org/entity/Q27022821

about

Cross Talk between Wnt/β-Catenin and CIP2A/Plk1 Signaling in Prostate Cancer: Promising Therapeutic Implications Addressing taxane resistance in metastatic castration-resistant prostate cancer: a focus on chaperone proteins.Up-Regulated Expression of LAMP2 and Autophagy Activity during Neuroendocrine Differentiation of Prostate Cancer LNCaP Cells Targeting Transcription Factors in Cancer Geraniol suppresses prostate cancer growth through down-regulation of E2F8 Overcoming HSP27-mediated resistance by altered dimerization of HSP27 using small molecules.Prostate cancer and the unfolded protein response.Novel agents for castration-resistant prostate cancer: Early experience and beyond.Impact of therapy on genomics and transcriptomics in high-risk prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy.A new model of multi-visceral and bone metastatic prostate cancer with perivascular niche targeting by a novel endothelial specific adenoviral vector.Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation.Lin28 induces resistance to anti-androgens via promotion of AR splice variant generation.Androgen receptor targeted therapies in castration-resistant prostate cancer: Bench to clinic.Recent advances in circulating tumor cells and cell-free DNA in metastatic prostate cancer: a review.BET bromodomain-mediated interaction between ERG and BRD4 promotes prostate cancer cell invasion.Targeting ACLY sensitizes castration-resistant prostate cancer cells to AR antagonism by impinging on an ACLY-AMPK-AR feedback mechanism.Modulation of paracrine signaling by CD9 positive small extracellular vesicles mediates cellular growth of androgen deprived prostate cancer.ROS-independent Nrf2 activation in prostate cancer Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer.Extracellular Vesicles in the Adaptive Process of Prostate Cancer during Inhibition of Androgen Receptor Signaling by Enzalutamide.Dysregulated fibronectin trafficking by Hsp90 inhibition restricts prostate cancer cell invasion.SEMA3C drives cancer growth by transactivating multiple receptor tyrosine kinases via Plexin B1.PARP inhibition in castration-resistant prostate cancer.Novel Androgen Receptor Coregulator GRHL2 Exerts Both Oncogenic and Antimetastatic Functions in Prostate Cancer.PP2A inhibition as a novel therapeutic target in castration-resistant prostate cancer.Evidenced-based clinical practice guideline for prostate cancer (summary: Japanese Urological Association, 2016 edition).Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer.

P2860

Q28076060-B4E80393-1DA8-44A1-8BCE-B8994F767DDE Q30244818-BD23F7D6-1B0C-4DBF-9F0B-CB63D87DF5F8 Q36132777-288E35D1-B0DF-4EA1-BBAF-7946F0AB2894 Q36347511-BF853079-FD0A-42BC-9C9B-FD8542D8683C Q37373117-9CD08C01-BBD0-4A0E-BC2B-73104BDA7A58 Q37619720-29ED8FAB-F99B-4379-9E8E-2D468D700183 Q37619869-63270A6E-CFCA-4801-9BEB-74398EED632D Q38574684-E4737ED1-61F7-425B-92A6-9D8BED093C49 Q38607675-287EE9DD-37F8-42AE-805A-154E4859612C Q38720538-F5CDFD0F-3076-4201-9513-9A861F754EF5 Q38739244-DDB64669-671E-4481-889A-E4FF239753A4 Q38808170-9C683342-6829-4FB2-90C8-9DC23B1CBA37 Q38865487-560FF565-E5DB-4B8D-A6A6-5FB9361071A7 Q39454057-20717FD4-6620-49CA-BC28-48C2F7171C02 Q39737405-0D527291-076D-442A-B9CC-9A1C3CE2B78A Q39986242-3A690C01-DF5B-4542-AF6C-53E9B6AEE0C9 Q41592660-38BD824A-0B7E-42E3-8C40-FCFFE2649355 Q41852907-8C826A17-61DE-431F-A24A-561D072D417E Q47111629-47307B86-2C7F-436E-A713-CBEC18894E1E Q47438384-8E784566-939C-40FD-A3C3-8049BED1D7BF Q48121004-7E8FB569-9E0F-477A-99F4-82EDBA5FB7F8 Q48216846-F63CF825-D825-4B42-A4B5-6E05DA52FEA5 Q48246094-EC861AD1-A3C5-4B83-BF47-0C8A4C8831AC Q51019461-F59DB059-82D7-4562-B60E-24A44FF7FFAD Q53398122-62831D43-B053-4937-93EA-2451F6E39EE1 Q53734447-12136C40-8B13-4672-976D-E1194BAA5010 Q53787362-26565331-6D9E-426E-A86B-98E43207042F

P2860

Targeting the adaptive molecular landscape of castration-resistant prostate cancer

http://www.wikidata.org/entity/Q27022821

description

2015 nî lūn-bûn

@nan

2015 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Targeting the adaptive molecular landscape of castration-resistant prostate cancer

@ast

Targeting the adaptive molecular landscape of castration-resistant prostate cancer

@en

Targeting the adaptive molecular landscape of castration-resistant prostate cancer

@nl

type

label

Targeting the adaptive molecular landscape of castration-resistant prostate cancer

@ast

Targeting the adaptive molecular landscape of castration-resistant prostate cancer

@en

Targeting the adaptive molecular landscape of castration-resistant prostate cancer

@nl

prefLabel

Targeting the adaptive molecular landscape of castration-resistant prostate cancer

@ast

Targeting the adaptive molecular landscape of castration-resistant prostate cancer

@en

Targeting the adaptive molecular landscape of castration-resistant prostate cancer

@nl

P1433

Q27022821-C7B53460-2D8F-4E36-886A-79FCFED6A873

P1476

Q27022821-14164834-5D98-4E33-98A2-8D98B78B3BC9

P2093

Q27022821-455EE4CD-22DD-44C5-B6D0-CAD1037C638B

Q27022821-B7F47AED-6FA3-463B-B702-D154EFCBCE6F

P275

Q27022821-0654133F-FB74-4464-A9F4-9C0F0C9407CF

P2860

Q27022821-007D6F59-D587-42B3-A9D7-429777808095

Q27022821-01B8F8FA-16F3-4398-B398-28A2886BFB83

Q27022821-01CB7F79-5607-46C8-B1C0-02310622197A

Q27022821-03AFE5A5-B422-454D-83C2-17B6F88035A0

Q27022821-05B95F41-D12E-48A6-B274-31904E85371F

Q27022821-070E69D3-4BF1-44AC-8DDC-7FD7B0787286

Q27022821-07106B13-3A15-4379-B99B-3D32AEC24519

Q27022821-07598BB0-32F6-4806-90F2-3DB1192226E4

Q27022821-08D21F35-409B-40C7-B529-1B48E6541BAC

Q27022821-098F6B4D-7DB8-4437-9E07-8CA24DAB09E2

P304

Q27022821-4AEA4040-4DF2-410D-BB07-2D54F9A2A9CA

P31

Q27022821-226508A4-75EC-4B42-AF2E-608A917D9BFA

Q27022821-7D50CBAC-F92B-41FD-9985-173076ED98C2

P3181

Q27022821-15E5E178-5777-42DA-8676-903129A6D87A

P356

Q27022821-489EF033-955A-48D1-A532-8E92E351656B

P407

Q27022821-9CFCF75E-804A-4811-87F3-C6A737E5CFDC

P433

Q27022821-28294A35-51C3-471E-8A08-335956A2CA3B

P478

Q27022821-65B8107F-F5B6-4E1C-AE6C-A3F36D0C1380

P5008

Q27022821-777E57BB-CB34-46DD-9D6C-AFD16934CB2F

P577

Q27022821-2BF1822B-FE68-407C-8E8B-B6BCEA711945

Q27022821-4A0A3206-2713-48CD-B91D-2BF8A70BB3B0

P5875

Q27022821-C367C124-7904-44E4-8953-193F7DADDD5A

P698

Q27022821-2A7ED325-5347-4B6B-9771-B70EB92D508D

P921

Q27022821-374DEEE3-DE16-4EC0-8F05-D91D1A517D52

Q27022821-666C3247-813C-4580-8EA9-9D1CFA486CE9

Q27022821-B5C9A84E-435B-4066-9289-1D74C50078F9

P932

Q27022821-195978EE-ACA2-41D0-B5D5-D0595AA61BFC

P3181

P356

P1433

EMBO Molecular Medicine

P1476

Targeting the adaptive molecular landscape of castration-resistant prostate cancer

@en

P2093

A. W. Wyatt

http://www.w3.org/2001/XMLSchema#string

M. E. Gleave

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer

Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

Abiraterone in metastatic prostate cancer without previous chemotherapy

Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis

Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6

Liquid biopsies: genotyping circulating tumor DNA

P304

878-94

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3299939

http://www.w3.org/2001/XMLSchema#string

P356

10.15252/EMMM.201303701

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2015-04-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2015-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

275413987

http://www.w3.org/2001/XMLSchema#string

P698

25896606

http://www.w3.org/2001/XMLSchema#string

P921

intracellular receptor

castration-resistant prostatic neoplasm

biological adaptation

P932

4520654

http://www.w3.org/2001/XMLSchema#string